CN101797324A - Medicinal composition for treating leukemia - Google Patents
Medicinal composition for treating leukemia Download PDFInfo
- Publication number
- CN101797324A CN101797324A CN201010113296A CN201010113296A CN101797324A CN 101797324 A CN101797324 A CN 101797324A CN 201010113296 A CN201010113296 A CN 201010113296A CN 201010113296 A CN201010113296 A CN 201010113296A CN 101797324 A CN101797324 A CN 101797324A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- placenta hominis
- described pharmaceutical
- leukemia
- cornu cervi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a medicinal composition for treating leukemia, which can directly treat leukemia and also has very good recovery effect on weak health caused by chemo-treatment for treating leukemia. The medicinal composition comprises the following components in weight ratio: 4 to 8 of maza, 1 to 2 of common yam rhizome, 3 to 5 of mix-fried tortoise plastron, 1 to 3 of hairy antler and 2 to 6 of root of rehmannia.
Description
Technical field
The present invention relates to treat leukemic pharmaceutical composition.Can directly treat leukemia, simultaneously the physical weakness due to the chemotherapeutic treatment leukemia be had good restitution.
Background technology
1. leukemia brief introduction
Leukemia is one group of heterogeneous malignant clone disease, be the hemopoietic system malignant tumor that causes of hematopoietic stem cell or CFU-GM sudden change. base mainly shows as abnormal blood cell (being the leukaemia) hypertrophy out of control in bone marrow and other hemopoietic tissue, soak into various tissues, and the normal hematopoiesis function is suppressed, normal plasma cell generates and reduces, produce corresponding clinical manifestation, on every side hemocyte have quality and quantity variation (practical internal medicine editorial board. practical internal medicine (volume two). Beijing: People's Health Publisher (2009 the 13rd edition) .2009:2482..
Leukemia is a kind of common malignancy, accounts for cancer and always falls ill about the 3-5% of number.Total annual morbidity is 8-10/10 ten thousand people.Leukemia accounts for the 6th (male) and the 8th (women) in each age group mortality of malignant tumors of China.
3 years (1973-1975) retrospective surveys of China's malignant tumor, leukemia corrected mortality male is 2.79/10 ten thousand, the women is 2.23/10 ten thousand.After the seventies in 20th century, along with updating of chemotherapy regimen and hematopoietic stem cell transplantation technology, existing more patient can long term survival.
2. existing medicine
By state of an illness emergency, leukemia is divided into acute and chronic, is divided into marrow again by differentiation degree, different subtypes such as pouring property.Leukemic treatment is to remove intravital leukaemia on the one hand, is the supporting treatment that the diseases such as secondary infection that produce behind the cases with leukemia are taked on the one hand in addition, with disease controlling.
A) non-drug therapy comprises methods such as hematopoietic stem cell transplantation and radiotherapy.
Hematopoietic stem cell transplantation is in conjunction with chemotherapeutics at present, and the assembly rate of depositing can reach more than 50% in 5 years.But allogene hematopoietic stem cell risk is bigger, and joins type and be difficult for, and the patient that can receive treatment is less relatively.Thought in the past that autologous stem cell transplantation was better than simple chemotherapy, its shortcoming is the relapse rate height, does not still have unified saying for its time-to-live and reason.In recent years along with the appearance of leukemia new drug and chemotherapy regimen improvement, especially the application in consolidating and strengthening treatment stage such as HDAC, the status that autologous stem cell is implanted among this group AML is under suspicion, and at present more domestic and international Clinical Research Centers have to be abandoned the trend of autologous stem cell as the first-line treatment measure after alleviating first.
B) chemical medicine and biological medicine.
Being used for the treatment of leukemic medicine has hydroxyurea, interferon, imatinib mesylate, Dasatinib, dexamethasone, chemical synthetic drug and biological medicines such as daunorubicin, methotrexate, vincristine, cytosine arabinoside.In addition, Chinese medicine is also being brought into play certain effect aspect the leukemic treatment.
Chemical medicine and biological medicine are mainly used in present leukemic treatment, and the leukemic state of an illness is had certain control action.But also exist the use that some problems are restricting medicine at present, the one, therapeutic effect is relatively limited, the 2nd, to the leukaemia to medicine insensitive and drug resistance problem, the 3rd, all in various degree exist side effect.
C) tcm therapy
The traditional Chinese medical science does not have this title of leukemia, but the clinical main feature of this pathogen is heating, anemia, and the record of diseases such as hemorrhage, hepatosplenomegaly sporadically appears in the successive dynasties document.Belong to chronic consumptive disease, categories such as acute pulmonary tuberculosis, hot consumptive disease.Hemorrhage owing to having, also belong to mass formed by blood stasis, and heating is similar to damp disease, hepatosplenomegaly obviously can be referred to as little long-pending, and lymphadenectasis obvious person can claim sucutaneous nodule or scrofula.
Chinese medicine is used for the treatment of white blood at present, based on auxiliary treatment, and on medication prescription and therapeutic scheme, the suggestion of not reaching an agreement as yet.
3. treat leukemic pharmaceutical composition
Pharmaceutical composition that is used for leukemia treating and the part by weight that the present invention relates to are:
Placenta Hominis 4-8 Rhizoma Dioscoreae 1-2 Carapax Et Plastrum Testudinis (processed) 3-5 Cornu Cervi Pantotrichum 1-3 Radix Rehmanniae 2-6
It is characterized in that the Placenta Hominis described in the compositions is Placenta Hominis (people's Placenta Hominis).
It is characterized in that the Placenta Hominis in the compositions is animal Placenta Hominis, Foetus Caprae seu Ovis and Embryo cervi.
It is characterized in that the Cornu Cervi Pantotrichum in the compositions is spotted deer antler, or the Cervus elaphus linnaeus Cornu Cervi Pantotrichum.
It is characterized in that, after compositions adds the pharmacy acceptable auxiliary, make granule, capsule, tablet, powder, pill, oral liquid application.
Embodiment 1:
The Placenta Hominis 300g Rhizoma Dioscoreae 40g Carapax Et Plastrum Testudinis (processed) 150g spotted deer antler 60g Radix Rehmanniae 200
Earlier Placenta Hominis, Rhizoma Dioscoreae, spotted deer antler, Carapax Et Plastrum Testudinis (processed), the Radix Rehmanniae are ground into fine powder, add 350g starch, mix homogeneously is made 1000g, as powder, and oral application.
Embodiment 2:
Embryo cervi 160g medicine 40g Carapax Et Plastrum Testudinis (processed) 120g spotted deer antler 40g Radix Rehmanniae 80g
Earlier Embryo cervi, Rhizoma Dioscoreae, spotted deer antler, Carapax Et Plastrum Testudinis (processed) are ground into fine powder, the Radix Rehmanniae adds 8 times of amounts of water and decocts twice, each 40 minutes, filter, merging filtrate is concentrated to relative density 1.25 (80 ℃), mix with above-mentioned fine powder, add the appropriate amount of starch Mel good, make 100 balls (honeyed pill) with refining.
Embodiment 3:
Placenta caprae seu ovis 190g Rhizoma Dioscoreae 40g Carapax Et Plastrum Testudinis (processed) 150g spotted deer antler 60g Radix Rehmanniae 180g
Earlier Placenta caprae seu ovis, Rhizoma Dioscoreae, Cornu Cervi Pantotrichum, Carapax Et Plastrum Testudinis (processed) are ground into fine powder, mix homogeneously, the Radix Rehmanniae add 8 times of amounts of water and decoct twice, each 40 minutes, filter, merging filtrate is concentrated to relative density 1.25 (80 ℃), mixes with above-mentioned fine powder, add appropriate amount of starch, the general one-tenth ball of water is made 1000 balls (watered pill).
Embodiment 4:
Embryo cervi 320g Rhizoma Dioscoreae 40g Carapax Et Plastrum Testudinis (processed) 200g spotted deer antler 120g Radix Rehmanniae 240g
Earlier Embryo cervi, Rhizoma Dioscoreae, Cornu Cervi Pantotrichum, Carapax Et Plastrum Testudinis (processed) (pulverizing), the Radix Rehmanniae are added 8 times of amounts of water and decoct twice, each 40 minutes, filter, merging filtrate is concentrated to relative density 1.08 (80 ℃), adds an amount of Icing Sugar, caramel, make the 2000ml oral liquid, packing, roll lid, the sterilization, promptly.
Embodiment 5:
Placenta caprae seu ovis 160g Rhizoma Dioscoreae 80g Carapax Et Plastrum Testudinis (processed) 120g cervus elaphus linnaeus 40g Radix Rehmanniae 80g
Earlier Placenta caprae seu ovis, Rhizoma Dioscoreae, Cornu Cervi Pantotrichum, Carapax Et Plastrum Testudinis (processed) (pulverizing), the Radix Rehmanniae are added 8 times of amounts of water and decoct twice, each 40 minutes, filter, merging filtrate is concentrated to relative density 1.25 (80 ℃), adds appropriate amount of starch and dextrin, is pressed into tablet.
Embodiment 6:
Placenta Hominis 250g Rhizoma Dioscoreae 60g Carapax Et Plastrum Testudinis (processed) 180g spotted deer antler 70g Radix Rehmanniae 180g
Earlier Placenta Hominis, Cornu Cervi Pantotrichum, Carapax Et Plastrum Testudinis (processed) are ground into fine powder, Rhizoma Dioscoreae, the Radix Rehmanniae add 8 times of amounts of water and decoct twice, each 40 minutes, filter, merging filtrate is concentrated to relative density 1.25 (80 ℃), adds above-mentioned fine powder, sneak into appropriate amount of starch and dextrin, granulate, incapsulate.
Embodiment 7:
Placenta Hominis 280g Rhizoma Dioscoreae 40g Carapax Et Plastrum Testudinis (processed) 170g spotted deer antler 60g Radix Rehmanniae 100g
Earlier Placenta Hominis, Cornu Cervi Pantotrichum, Carapax Et Plastrum Testudinis (processed) are ground into fine powder, Rhizoma Dioscoreae, the Radix Rehmanniae add 8 times of amounts of water and decoct twice, each 40 minutes, filter, merging filtrate is concentrated to relative density 1.25 (80 ℃), adds above-mentioned fine powder, sneaks into appropriate amount of starch and dextrin, granulate, packing is made granule.
Experimental example 1:
Grandson X, the man, 16 years old, Harbin City, Heilongjiang Province people from city, 1995, feel uneasy, often the heating, after move in the People's Hospital, Heilongjiang Province, be chronic myelocytic leukemia after diagnosing.Treat about half a year, the state of an illness is controlled to some extent, but still can not break away from Drug therapy.Because of economic cause, the recuperation of going home of leaving hospital, and seek Chinese traditional treatment.In August, 1997, I see the patient, an emaciated, dried-up appeance, and the deficiency of vital energy is weak, light red tongue, moderate pulse and unable.I accuse it with the method for embodiment 1, and the patient goes home to make by oneself powder and takes, every day 30g.Further consultation after January, it is glossy to have rosy cheeks, and the weak remission of readme can be carried out some physical exercises, and light red tongue is a little less than the moderate pulse.Drug effect has certain effect, advises it to continue to take then.Further consultation again after half a year, shape and color such as ordinary person, the red tongue tire is thin white, faint and rapid pulse.The readme health recovers substantially, goes to the province the People's Hospital to check that all are normal.
Experimental example 2:
Field XX, man, 15 years old, Shuangcheng people from county, Harbin City, Heilongjiang Province city.2001,, be diagnosed as and be anxious myelogenous leukemia through breathing out the Second Academy of medical university because of heating is in hospital.Go to Tianjin treatment about a year, because of economic cause, the recuperation of going home of leaving hospital.In JIUYUE, 2003 is sought medical advice in me, because of Placenta Hominis be difficult for is obtained, then accuses it with the method for embodiment 2, and the patient goes home to make by oneself and takes, every days 2 ball g.Go to Heilongjiang Prov. Tumour Hospital to check that all are normal after 1 year.
Experimental example 3:
Guo XX, woman, 45 years old, Harbin City, Heilongjiang Province people from city.2002 come here to go to a doctor, and readme is a leukemia, carries out chemotherapy in tumour hospital, because of the chemotherapy side effect reason, alopecia, no appetite, health a little less than, the doctor advises that it carries out traditional Chinese medical science auxiliary treatment.Satisfy and come here to go to a doctor.For making things convenient for it to take, three of every days are taken in writing out a prescription with the foregoing description 6 of announcement.Here further consultation over 2003, the readme health has very big improvement, though examination in hospital not recovery from illness as yet, the doctor has advised its treatment of can recuperating in family.
Claims (7)
1. treat leukemic pharmaceutical composition for one kind, it is characterized in that it is to be made by the medicine of following weight ratio:
Placenta Hominis 4-8 Rhizoma Dioscoreae 1-2 Carapax Et Plastrum Testudinis (processed) 3-5 Cornu Cervi Pantotrichum 1-3 Radix Rehmanniae 2-6
2. the described pharmaceutical composition of claim 1 is characterized in that Placenta Hominis is Placenta Hominis (people's Placenta Hominis).
3. the described pharmaceutical composition of claim 1 is characterized in that Placenta Hominis is an Embryo cervi.
4. the described pharmaceutical composition of claim 1 is characterized in that Placenta Hominis is a Foetus Caprae seu Ovis.
5. the described pharmaceutical composition of claim 1 is characterized in that Cornu Cervi Pantotrichum is a spotted deer antler.
6. the described pharmaceutical composition of claim 1 is characterized in that Cornu Cervi Pantotrichum is the Cervus elaphus linnaeus Cornu Cervi Pantotrichum.
7. the described pharmaceutical composition of claim 1 is characterized in that, after compositions adds the pharmacy acceptable auxiliary, makes granule, capsule, tablet, powder, pill, oral liquid application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010113296.XA CN101797324B (en) | 2010-02-24 | 2010-02-24 | One treats leukemic pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010113296.XA CN101797324B (en) | 2010-02-24 | 2010-02-24 | One treats leukemic pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101797324A true CN101797324A (en) | 2010-08-11 |
| CN101797324B CN101797324B (en) | 2015-09-02 |
Family
ID=42593265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010113296.XA Expired - Fee Related CN101797324B (en) | 2010-02-24 | 2010-02-24 | One treats leukemic pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101797324B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796742A (en) * | 2016-05-24 | 2016-07-27 | 刘金海 | Traditional Chinese medicinal composition for treating chronic leukemia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1157166A (en) * | 1996-01-25 | 1997-08-20 | 温顺明 | Xuefukang medicine |
| CN101264278A (en) * | 2008-04-24 | 2008-09-17 | 廖玉春 | Chinese medicinal composition for treating leukemia and producing method thereof |
| CN101264279A (en) * | 2008-04-24 | 2008-09-17 | 廖玉春 | Chinese medicinal composition for treating common cancer and producing method thereof |
-
2010
- 2010-02-24 CN CN201010113296.XA patent/CN101797324B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1157166A (en) * | 1996-01-25 | 1997-08-20 | 温顺明 | Xuefukang medicine |
| CN101264278A (en) * | 2008-04-24 | 2008-09-17 | 廖玉春 | Chinese medicinal composition for treating leukemia and producing method thereof |
| CN101264279A (en) * | 2008-04-24 | 2008-09-17 | 廖玉春 | Chinese medicinal composition for treating common cancer and producing method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796742A (en) * | 2016-05-24 | 2016-07-27 | 刘金海 | Traditional Chinese medicinal composition for treating chronic leukemia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101797324B (en) | 2015-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101461921B (en) | Medicinal composition for treating gynecopathy | |
| CN102579803B (en) | Medicine for treating post-chemotherapy leucopenia and preparation method thereof | |
| CN101797324B (en) | One treats leukemic pharmaceutical composition | |
| CN101342343B (en) | Pharmaceutical composition for treating anemia | |
| CN100391506C (en) | Medicine for treating dementia and preparing method thereof | |
| CN102652774B (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| CN101461894A (en) | Medicament composition for treating female climacteric syndrome and delaying age | |
| CN101020026B (en) | Honeyed Guiqi ointment for enhancing body's resistance and its preparation | |
| CN101120997A (en) | Traditional Chinese medicine composition for strengthening spleen and stomach and nourishing liver and kidney and preparation method thereof | |
| CN103191371B (en) | Pharmaceutical composition for preventing/treating respiratory system disease and use of pharmaceutical composition | |
| CN101721612B (en) | Chinese medicinal composition for raising leucocytes and preparation method and application thereof | |
| CN105368672A (en) | Health-care wine containing phellinus | |
| CN105287943A (en) | Compound fructus cannabis capsules, preparation method and applications thereof | |
| CN104435259B (en) | The purposes of a kind of Chinese medicine composition in the bacillary mastitis medicament of preparation treatment | |
| CN101559196B (en) | Medicament for treating the hyperplasia of mammary glands and preparation method thereof | |
| CN1957967A (en) | Application of pseudostellaria root for preparing medication of treating cardiovascular disease | |
| CN103223088A (en) | Traditional Chinese medicine for treating yin deficiency and blood stasis syndrome of Parkinson's disease | |
| CN100376257C (en) | A medicine for treating coronary atherosclerotic heart disease | |
| CN101953994B (en) | Chinese medicament for treating luekopenia after concurrent chemoradiotherapy | |
| CN103784799B (en) | A kind of Chinese medicine composition for the treatment of alpastic anemia | |
| CN113288951A (en) | Blood-increasing traditional Chinese medicine composition and preparation method thereof | |
| CN105250500A (en) | Medicine composition for treating dyspepsia | |
| CN1222377A (en) | Hypertension ointment for external use | |
| CN1504231A (en) | Medicine for tumour | |
| CN115869372A (en) | A Chinese medicinal composition with tranquilizing and analgesic effects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Gu Ming Document name: Notice of termination of patent right |
|
| DD01 | Delivery of document by public notice | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150902 Termination date: 20210224 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |